Sensex: 82201.16 (-1.24%)

Nifty: 24852.15 (-1.17%)

anubhai angaldas Securities Pvt. Ltd. Member: BSE - NSE - CDSL

Technology . Transparency . Trust

Contact Us
Apply For IPO

MARKET

Hot Pursuit
Strides Pharma launches Icosapent ethyl acid soft gel capsules
02-Dec-2023 14:26
Icosapent ethyl acid soft gel capsules 0.5g and 1g is an ethyl ester of eicosapentaenoic acid (EPA) that is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (500 mg/dL) hypertriglyceridemia.

The said product has been in-licensed from Strides and will be commercialized by Amneal starting in the fourth quarter of 2023. It is being launched in the US in partnership with Amneal Pharmaceuticals, a fully integrated global pharmaceuticals company.

Aditya Kumar, vice president business development, Strides Pharma Science, said, ?We are thrilled to announce our partnership with Amneal Pharmaceuticals for Icosapent ethyl acid soft gelatin capsules. This partnership is a testament to our commitment to excellence and the pursuit of cutting edge solutions. By combining our resources, expertise, and shared passion, we are confident that we will achieve remarkable outcomes that benefit not only our organizations but also our valued customer and stakeholders.

Andy Boyer, executive vice president, Amneal Generics, said, ?We are on-track to launch over 40 new products in 2023. The launch of Icosapent ethyl is another essential medicine that we?ve added to our portfolio.?

Bengaluru-based Strides Pharma Science is a global pharmaceutical company. The company mainly operates in the regulated markets and has an in Africa for Africa strategy and an institutional business to service donor-funded markets. The company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi), and the United States (New York).

The company reported a consolidated net loss (from continuing operations) of Rs 149.46 crore in Q2 FY24 as against a net profit of Rs 0.33 crore posted in Q2 FY23. The company reported quarterly sales of Rs 1,026.4 crore in Q2 FY24, registering a growth of 21% from Rs 848.20 crore in Q2 FY23.

The scrip rallied 3.30% to Rs 502.65 on Friday, 1 December 2023.

Powered by Capital Market - Live News

Attention Investor
As per CDSL communiqué Kindly update your Email ID, Mobile Number & Income Range in CDSL demat Account on or before 31st May 2021, Non Compliance Account will be INACTIVE after 31st May 2021. | Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors.  | "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account." | "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."    Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of Investors.